Literature DB >> 17846314

Persistent reduction of ischemic mitral regurgitation by papillary muscle repositioning: structural stabilization of the papillary muscle-ventricular wall complex.

Judy Hung1, Miguel Chaput, J Luis Guerrero, Mark D Handschumacher, Lampros Papakostas, Suzanne Sullivan, Jorge Solis, Robert A Levine.   

Abstract

BACKGROUND: Recurrent ischemic mitral regurgitation (IMR) is frequent despite initial reduction by annuloplasty because continued LV remodeling increases tethering to the infarcted papillary muscle (PM). We have previously shown that PM repositioning by an external patch device can acutely reduce IMR. In this study, we tested the hypothesis that IMR reduction persists despite possible continued LV remodeling. METHODS AND
RESULTS: In 7 sheep, we used a chronic ischemic posterior infarct model that produces LV dilatation and MR over 10 weeks. An epicardial patch device was adjusted under echo guidance to reduce MR, with follow-up over a further 8 weeks and evaluation by 3D echo and sonomicrometry. In all 7 sheep, moderate IMR resolved with acute patch application and PM repositioning (6.5+/-1.8 mm to 0.6+/-1.3 mm proximal jet width, P<0.001) without decrease in LVEF (43+/-3% to 44+/-8%). Eight weeks after PM repositioning, MR was not significantly greater (0.6+/-1.3 mm versus 1.0+/-1.0 mm, P=NS) despite an increase in LV volumes in 3 animals (2 had increases of 50+/-15%). On average, LV volumes did not change significantly (ESV: 46+/-8 mL versus 49+/-15 mL; P=NS and EDV: 85+/-16 mL versus 89+/-30 mL; P=NS). LVEF was unchanged from acute to chronic patch (44+/-8% versus 43+/-8%). Contractility as end-systolic elastance did not decrease from the chronic MI to the acute and chronic patch stages, nor were there any significant changes in dP/dt, LV stiffness constant, or time constant of LV relaxation (Tau).
CONCLUSION: PM repositioning is persistently effective in reducing moderate chronic IMR, even when LV volume increases. This may reflect structural stabilization by an external patch device of the papillary muscle-LV wall complex that controls mitral valve tethering.

Entities:  

Mesh:

Year:  2007        PMID: 17846314     DOI: 10.1161/CIRCULATIONAHA.106.679951

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

Review 1.  Mitral valve disease--morphology and mechanisms.

Authors:  Robert A Levine; Albert A Hagége; Daniel P Judge; Muralidhar Padala; Jacob P Dal-Bianco; Elena Aikawa; Jonathan Beaudoin; Joyce Bischoff; Nabila Bouatia-Naji; Patrick Bruneval; Jonathan T Butcher; Alain Carpentier; Miguel Chaput; Adrian H Chester; Catherine Clusel; Francesca N Delling; Harry C Dietz; Christian Dina; Ronen Durst; Leticia Fernandez-Friera; Mark D Handschumacher; Morten O Jensen; Xavier P Jeunemaitre; Hervé Le Marec; Thierry Le Tourneau; Roger R Markwald; Jean Mérot; Emmanuel Messas; David P Milan; Tui Neri; Russell A Norris; David Peal; Maelle Perrocheau; Vincent Probst; Michael Pucéat; Nadia Rosenthal; Jorge Solis; Jean-Jacques Schott; Ehud Schwammenthal; Susan A Slaugenhaupt; Jae-Kwan Song; Magdi H Yacoub
Journal:  Nat Rev Cardiol       Date:  2015-10-20       Impact factor: 32.419

Review 2.  Basic mechanisms of mitral regurgitation.

Authors:  Jacob P Dal-Bianco; Jonathan Beaudoin; Mark D Handschumacher; Robert A Levine
Journal:  Can J Cardiol       Date:  2014-07-02       Impact factor: 5.223

3.  Characterization of 3-dimensional papillary muscle displacement in in vivo ovine models of ischemic/functional mitral regurgitation.

Authors:  Wolfgang Bothe; Tomasz A Timek; Frederick A Tibayan; Mario Walther; George T Daughters; Neil B Ingels; D Craig Miller
Journal:  J Thorac Cardiovasc Surg       Date:  2018-10-10       Impact factor: 5.209

4.  Mitral regurgitation after anteroapical myocardial infarction: new mechanistic insights.

Authors:  Chaim Yosefy; Ronen Beeri; J Luis Guerrero; Mordehay Vaturi; Marielle Scherrer-Crosbie; Mark D Handschumacher; Robert A Levine
Journal:  Circulation       Date:  2011-03-28       Impact factor: 29.690

Review 5.  Anatomy of the mitral valve apparatus: role of 2D and 3D echocardiography.

Authors:  Jacob P Dal-Bianco; Robert A Levine
Journal:  Cardiol Clin       Date:  2013-04-15       Impact factor: 2.213

6.  Efficacy of polymer injection for ischemic mitral regurgitation: persistent reduction of mitral regurgitation and attenuation of left ventricular remodeling.

Authors:  Xin Zeng; Lin Zou; Robert A Levine; J Luis Guerrero; Mark D Handschumacher; Suzanne M Sullivan; Gavin J C Braithwaite; James R Stone; Jorge Solis; Orhun K Muratoglu; Gus J Vlahakes; Judy Hung
Journal:  JACC Cardiovasc Interv       Date:  2015-01-14       Impact factor: 11.195

Review 7.  Three-dimensional echocardiography. New possibilities in mitral valve assessment.

Authors:  Jorge Solis; Marta Sitges; Robert A Levine; Judy Hung
Journal:  Rev Esp Cardiol       Date:  2009-02       Impact factor: 4.753

8.  A novel approach for reducing ischemic mitral regurgitation by injection of a polymer to reverse remodel and reposition displaced papillary muscles.

Authors:  Judy Hung; Jorge Solis; J Luis Guerrero; Gavin J C Braithwaite; Orhun K Muratoglu; Miguel Chaput; Leticia Fernandez-Friera; Mark D Handschumacher; Van J Wedeen; Stuart Houser; Gus J Vlahakes; Robert A Levine
Journal:  Circulation       Date:  2008-09-30       Impact factor: 29.690

9.  Mitral apparatus assessment by delayed enhancement CMR: relative impact of infarct distribution on mitral regurgitation.

Authors:  Jason S Chinitz; Debbie Chen; Parag Goyal; Sean Wilson; Fahmida Islam; Thanh Nguyen; Yi Wang; Sandra Hurtado-Rua; Lauren Simprini; Matthew Cham; Robert A Levine; Richard B Devereux; Jonathan W Weinsaft
Journal:  JACC Cardiovasc Imaging       Date:  2013-02

10.  Mitral leaflet adaptation to ventricular remodeling: prospective changes in a model of ischemic mitral regurgitation.

Authors:  Miguel Chaput; Mark D Handschumacher; J Luis Guerrero; Godtfred Holmvang; Jacob P Dal-Bianco; Suzanne Sullivan; Gus J Vlahakes; Judy Hung; Robert A Levine
Journal:  Circulation       Date:  2009-09-15       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.